Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns

BACKGROUND: Tisagenlecleucel was approved by the Food and Drug Administration (FDA) in 2017 for refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-ALL in ≥2nd relapse. Outcomes of patients receiving commercial tisagenlecleucel upon 1st relapse have yet to be established. We aimed to report...

Descripción completa

Detalles Bibliográficos
Autores principales: Barsan, Valentin, Li, Yimei, Prabhu, Snehit, Baggott, Christina, Nguyen, Khanh, Pacenta, Holly, Phillips, Christine L., Rossoff, Jenna, Stefanski, Heather, Talano, Julie-An, Moskop, Amy, Baumeister, Susanne, Verneris, Michael R., Myers, Gary Douglas, Karras, Nicole A., Cooper, Stacy, Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, Christa, Keating, Amy, Fabrizio, Vanessa, Chinnabhandar, Vasant, Kunicki, Michael, Curran, Kevin J., Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632672/
https://www.ncbi.nlm.nih.gov/pubmed/37954907
http://dx.doi.org/10.1016/j.eclinm.2023.102268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632672/
https://www.ncbi.nlm.nih.gov/pubmed/37954907
http://dx.doi.org/10.1016/j.eclinm.2023.102268

Ejemplares similares